Literature DB >> 18652905

A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.

Susan Summerhill1, Timothy Stroud, Roshini Nagendra, Christelle Perros-Huguet, Michael Trevethick.   

Abstract

INTRODUCTION: The aim was to establish a robust, 96-well, cell-based assay to assess the potency and persistence of action of agonists acting at human recombinant beta(2) adrenoceptors expressed in CHO (Chinese Hamster Ovary) cells and to compare this with published duration of action data in guinea pig isolated trachea and human bronchus.
METHODS: Cells were treated with either: (i) beta-adrenoceptor agonist for 30 min, washed and cyclicAMP (cAMP) measured 30 min later-termed 'washed' cells or, (ii) treated with solvent for 30 min, washed, and then treated with beta-adrenoceptor agonist for 30 min and cAMP measured-termed 'unwashed' cells. The 'washed' EC(50) was divided by the 'unwashed' EC(50) to determine a rightward shift concentration ratio, which was indicative of the persistence of action at the receptor.
RESULTS: At the beta(2) adrenoceptor salmeterol, carmoterol and indacaterol were resistant to washing with a concentration ratio of <5, indicating a long persistence of action, whereas formoterol, isoprenaline and salbutamol were washed out with a ratio of 32, >294 and >800 respectively, suggesting a shorter persistence of action. At beta(1) and beta(3) adrenoceptors all compounds washed out. The persistent effects of salmeterol at beta(2) following washing could be reversed by the selective beta(2) antagonist ICI 118551, suggesting continued receptor activation. DISCUSSION: The data presented agree well with published data assessing duration of action of beta(2) agonists in human isolated bronchus and guinea pig isolated trachea. Key features are: (a) it is a 96-well format which can be used to assess many compounds in a single experiment, (b) both potency and persistence of agonist action are assessed in the same assay, (c) any effects of concentration on the persistence of action can be highlighted, and (d) it allows triage of compounds prior to tissue bath studies thus reducing the use of animal tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652905     DOI: 10.1016/j.vascn.2008.06.003

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  6 in total

1.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists.

Authors:  David A Sykes; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  β(2) -adrenoceptor agonists: current and future direction.

Authors:  Mario Cazzola; Luigino Calzetta; Maria Gabriella Matera
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

4.  Development of a membrane-anchored chemerin receptor agonist as a novel modulator of allergic airway inflammation and neuropathic pain.

Authors:  Jamie R Doyle; Subrahmanian T Krishnaji; Guangli Zhu; Zhen-Zhong Xu; Daniel Heller; Ru-Rong Ji; Bruce D Levy; Krishna Kumar; Alan S Kopin
Journal:  J Biol Chem       Date:  2014-03-21       Impact factor: 5.157

5.  Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Caterina Branca; Elena V Wisely; Lauren K Hartman; Antonella Caccamo; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2014-06-16       Impact factor: 4.673

6.  Discovery of dual-action membrane-anchored modulators of incretin receptors.

Authors:  Jean-Philippe Fortin; Daniel Chinnapen; Martin Beinborn; Wayne Lencer; Alan S Kopin
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.